FDA approved zilganersen as the first disease-modifying therapy for Alexander disease, an ultra-rare, progressive ...
In a conversation with Pharmaceutical Executive, Nate Hill, Co-Founder & CEO of Strive Pharmacy, discussed the regulatory ...
Apazunersen did not improve validated measures of cognition/nonverbal reasoning or an integrated multi-domain responder endpoint, with no treatment–placebo difference supportive of efficacy.
Ionis wins FDA approval for Zanvastro, the first disease-modifying treatment for Alexander disease, Pharmaceutical ...
Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...
Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...
Novartis instituted program-wide clinical holds across eight Rap‑cel autoimmune trials after three IEC‑HS events with fatal outcomes, prompting regulator engagement and comprehensive cross-program ...
Eli Lilly agrees to acquire Merida Biosciences for up to $2.875 billion, BioNTech halts a Phase II trial of its cancer ...
The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...
Recently, Pharmaceutical Executive spoke with Christian Thienel, director at Back Bay Life Sciences, about the ongoing issues ...
Nate Hill, co-founder & CEO, Strive, notes the key milestone to watch for during the remaining step in FDA's formal Category ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results